Dr. Vincent Gau to Present GeneFluidics' Technology and
Corporate Development at the National Cancer Institute's
Biosensor Conference
MONTEREY PARK, CA - June 6, 2005 - GeneFluidics, Inc., a point
of care clinical diagnostic company, announced today that its
Chief Executive, Dr. Vincent Gau, will present the Company's
technological and corporate development progress at the
National Cancer Institute's conference entitled "Moving
Biosensors to Point-of-Care Cancer Diagnostics." This
conference will present novel technologies as well as foster
dialogue amongst cancer diagnostic researchers and biosensor
engineers. Dr. Gau will give two presentations, including "The
Clinical Application of Nanotechnology-Enabled Molecular
Analysis" and "Bionanotechnology Meets Microfluidics for 'Plug
and Play' Diagnostics." More information on the conference can
be found at https://cms.palladianpartners.com/cms/1111782287/.
About GeneFluidics:
GeneFluidics is commercializing a novel molecular analysis
platform that integrates bionanotechnology and microfluidics.
The platform has two distinct yet synergistic components -
electrochemical detection, embodied in a multichannel reader
and plastic sensor chips, and automated sample preparation,
embodied in microfluidic cartridges and associated reader
fluidic controls. By integrating these components, the
platform enables the rapid detection and quantification of
genetic material, proteins, and small molecules in raw samples
without the use of target amplification methods such as PCR.
CONTACT:
Vincent Gau
CEO
2540 Corporate Place, Suite B101
Monterey Park, CA 91754
323-269-0900
